After $152bn In Deals Could Allergan CEO Saunders Double His Money?
This article was originally published in Scrip
Executive Summary
Allergan plc CEO Brent Saunders traded up from the $8.7bn sale of Bausch & Lomb Inc. in 2013 to the $66bn merger of Allergan and Actavis plc earlier this year as the companies he helmed were acquired or made their own big buys, bringing the dealmaker's two-year transaction total to $152bn, and now Saunders could double that number if Pfizer Inc. proposes a suitable acquisition price for Allergan.